Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.
Bladder Cancer
DRUG: Oxaliplatin|DRUG: Taxotere
Tolerability of the this combination in patients with recurrent metastatic bladder cancer., 1 year
To test the combination of oxaliplatin chemotherapy in combination with taxotere chemotherapy in patients with advanced bladder cancer who have failed one prior chemotherapy.